{"id":"NCT02525549","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2015-08-17","resultsPosted":"2021-01-20","lastUpdate":"2021-11-02"},"enrollment":903,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"Adapalene and Benzoyl Peroxide Gel","otherNames":[]},{"type":"DRUG","name":"Adapalene and Benzoyl Peroxide Gel (Reference)","otherNames":[]},{"type":"DRUG","name":"Placebo gel","otherNames":[]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and bioequivalence of Perrigo's product to an FDA approved product for the treatment acne vulgaris.","primaryOutcome":{"measure":"Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions","timeFrame":"84 days","effectByArm":[{"arm":"Test Product","deltaMin":61.07,"sd":36.6},{"arm":"Reference Product","deltaMin":65.58,"sd":28.42},{"arm":"Placebo Product","deltaMin":41.63,"sd":28.05}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":365},"commonTop":[]}}